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Abstract
purpose We wished to evaluate the effectiveness of laparo-
scopic and open surgery for patients with rectum cancer
through a meta-analysis.
Methods We searched PubMed, EMBASE, and Cochrane da-
tabase until June 30, 2015, to identify eligible studies.
Randomized controlled trials comparing laparoscopic with
open surgery for rectum cancer were included. Meta-analysis
was performed using the search strategy following the require-
ment of the Cochrane Library Handbook. Three-year overall
survival (OS) and disease-free survival (DFS) were the main
endpoints.
Results Eight randomized controlled trials comprising 3145
patients matched the selection criteria. Meta-analysis showed
no significant difference between laparoscopic and open sur-
gery in 3-year overall survival (OS) and disease-free survival
(DFS) (hazard ratio (HR)3-year OS = 0.83, 95%CI [0.68–1.01];
P = 0.06; HR3-year DFS = 0.89, 95 % CI [0.75,1.05]; P = 0.16).
No evidence of publication bias was observed.
Conclusion Our meta-analysis supported the notion that based
on the 3-year DFS and OS, oncological outcomes are compa-
rable after laparoscopic and open surgery for rectal cancer.
Keywords Rectum cancer . Laparoscopy . Open surgery .
Survival rate . Meta-analysis
Introduction
Colorectal cancer is one of the most common malignant tu-
mors worldwide [1]. Its incidence rate in western developed
countries has been in the third place among all malignant
tumors and the fifth common malignant tumor in China
[2–4]. With the improvement of technology, the number of
therapeutic modalities available for rectal cancer has increased
dramatically.
In recent years, accumulating evidence indicate that
laparoscopic surgery was associated with lower blood
loss, earlier return of bowel movement, and reduced
length of hospital stay as compared to open surgery [5–7].
However, evidence is lacking to evaluate whether the long-
time survival after laparoscopic resection of rectal cancer is
not inferior to open surgery. As a result, the latest National
Comprehensive Cancer Network (NCCN) Clinical Practice
Guidelines for Rectal Cancer stated that BLaparoscopic sur-
gery is preferred in the setting of a clinical trial^ [8].
Although meta-analysis studying some of these trials had
shown equivalence, not all reported long-term data including
the Comparison of Open versus laparoscopic surgery for
mid or low REctal cancer After Neoadjuvant chemoradio-
therapy (COREAN) trial. More recently, the COlorectal can-
cer Laparoscopic or Open Resection (COLOR II) trial has
released 3-year survival rates that can now be included. It is
necessary to update the result of meta-analysis.
The aim of this paper was to perform a meta-analysis of 3-
year survival rates of the clinical trials to evaluate the effec-
tiveness of laparoscopy and open surgery for rectum cancer.
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We searched for relevant studies according to the search strat-
egy of the Cochrane Collaboration [9]. Two of the authors
independently completed an online search of PubMed,
Embase, and Cochrane library for studies for RCTs that com-
pared laparoscopic with open surgery for rectal cancer. The
following search terms were used: Brectum cancer [Mesh]/
colorectal neoplasms/colorectal cancer/colorectal tumor/
colorectal adenocarcinoma/rectal neoplasms/rectal cancer/rec-
tal tumor/rectal adenocarcinoma/rectum neoplasms/
rectum cancer/rectum tumor/rectum adenocarcinoma,^
802 records identified through 
database searching(678 from 
Pubmed, 74 from Embase, 50 from 
Cochrane library)
115 records after duplicates removed
80 records excluded:
Non-relevant studies(including 




35 full-texts articles assessed for 
eligibility
115 titles and abstracts screened
27 Full-texts articles excluded:
Non-RCTs studies: 17
Insufficient outcome: 10
8 RCTs included in the final meta-
analysis
















Fig. 1 Number of rectum cancer patients included in the meta-analysis
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Blaparoscopy[Mesh]/laparoscopy/laparoscope/laparoscopic,^
and Blaparotomy[Mesh]/open surgery/open abdominal
surgery/conventional surgery/laparotomy.^ No language lim-
itation or other restrictions such as research design was im-
posed in this search. The search included literature published
until April 2015with no lower date limit. The computer search
was supplemented with manual searches for references of in-
cluded studies. The reference lists of obtained studies were
also reviewed to identify relevant citations. The abstracts or
full text of all potentially relevant studies were independently
scrutinized by two reviewers; any disagreements were re-
solved and reached a consensus after discussion. All the re-
sults were limited by Brandomized controlled trials^.
Inclusion and exclusion criteria of trials
To be eligible for the meta-analysis, the following selection
criteria were set: (1) treatment of rectum cancer by laparosco-
py versus open surgery, (2) prospective randomized controlled
clinical trial, (3) the age of the patient population should be
over 18 years, and (4) the description of the details of 3-year
overall survival rate (OS) and disease-free survival (DFS) rate.
Studies were excluded if they did not have appropriate data
or could not able to extract available data from the published
result, and [3] deal with recurrent rectum cancer or metastatic
carcinoma.
Qualitative analysis
The risk of bias in RCTs was assessed following Cochrane
recommendations, considering random sequence generation,
allocation concealment, blinding of participants and person-
nel, blinding of outcome assessment, incomplete outcome da-
ta, and selective reporting [9]. Each category was assessed as
yes (low risk of bias), unclear, or no (high risk of bias), and
summarized in a table with plus, question mark, or minus
signs, respectively.
Publication bias was evaluated by funnel plots and Egger’s
regression [10].
Statistical analysis
Log hazard ratios and their variance were used as the summa-
ry outcome measure from all trials in the meta-analysis. For
each trial, hazard ratios (HR) with the 95 % confidence inter-
val (95 % CI) of the survival rate was derived and calculated
using either the fixed-effects model or the random-effects
model [11]. For each meta-analysis, Cochrane’s Q statistic
was first calculated to assess the heterogeneity between stud-
ies. For P values less than 0.1, the assumption of homogeneity
was deemed invalid, and the random effects model was used;
otherwise, data were assessed using the fixed-effects model.
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publication bias. Statistical analysis was independently per-
formed by two statisticians using the software program
Review manager (version 5.1).
As Marco Braga’s trial reported Dukes staging, Dukes A,
B, and combined C1 and C2 were treated as stages I, II, and III
for the purposes of inclusion in the final analysis by stage
(American Joint Committee on Cancer).
Results
Study identification and quality assessment
A total of 802 studies were identified by the electronic
searches. After excluding duplicates, 115 articles remained,
80 of which were excluded: 63 were not relevant, 7 were case
Fig. 2 Quality assessment of
included RCTs
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series/case reports, and 10 were reviews/letters/comments.
Thirty-five considered articles were reviewed in depth, and a
full examination of the text was performed. Seventeen studies
were excluded because they were non-RCTstudies. 10 studies
were excluded because of the insufficient outcome. At last,
eight studies involving a total of 3145 rectum cancer patients
were included into this meta-analysis [12–19] (Fig. 1)
(Table 1).
The quality assessment of included RCTs was performed
using Cochrane Collaboration’s tool. In these studies, blinding
techniques were hardly feasible because of the different treat-
ment procedures and the associated adverse effects. However,
the review authors judge that the outcome is not likely to be
influenced by lack of blinding. The risk of incomplete out-
come data addressing, selective reporting, and other bias were
not apparent across studies (Fig. 2).
Meta-analysis results
Overall survival rate
Data for 3-year overall survival rate were reported in eight
trials, and there was no heterogeneity among those trials
(P=0.06); thus, the fixed-effects model was used to pool the
results. Data showed that no significant difference was found
between the laparoscopy group and the open surgery group
(HR=0.83, 95 % CI [0.68, 1.01]; P=0.06) (Fig. 3).
Disease-free survival
Data for 3-year disease-free survival rate were reported in
seven trials, and there was no heterogeneity among those
trials (P= 0.16); thus, the fixed-effects model was used to
pool the results. Data showed that no significant differ-
ence was found between the laparoscopy group and the
open surgery group (HR = 0.89, 95 % CI [0.75, 1.05];
P= 0.16) (Fig. 4).
The stage subgroup analysis
Three trials reported the data for 3-year disease-free survival
rate in stages I, II, and III. The fixed-effects model was used to
pool the results. Data showed that there was no significant
heterogeneity in stage I (P=0.23), stage II (P=0.50), and
stage III (P=0.50). Only two trials reported the data for 3-
year overall survival rate and the data was not enough for a
meta-analysis (Fig. 5).
Publication bias
The publication bias in this study was detected using a funnel
plot of the meta-analysis result. The basic symmetry of the
funnel plot suggested that there was no obvious publication
bias in this meta-analysis. The Egger’s test for 3-year overall
survival rates, 3-year disease-free survival rates, and the stage
subgroup did not show any evidence of publication bias.
Discussion
After the first report of laparoscopic colon resection in 1991
[20], laparoscopic surgery has progressively replace open co-
lonic surgery in recent years for its short-term benefits and
equivalent long-term survival [21]. But for rectal cancer, the
evidence is still lacking for the oncological outcome between
the two techniques. The golden standard to evaluate a tech-
nique for cure malignant cancer is whether the technique can
adhere to the oncological standard of care. So, we preformed
this meta-analysis to compare laparoscopic with open surgery
for rectal cancer.
In the present meta-analysis, we examined the 3-year sur-
vival with the largest sample size using the time-to-event out-
come and log hazard ratio to compare the two techniques for
rectal cancer. As we know, time-to-event outcomes take ac-
count of whether an event takes place and also the time at
which the event occurs, such that both the event and the timing
of the event are important [22]. In survival analysis, the hazard
Fig. 3 Overall survival rate reported in eight trials
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ratio is the ratio of the hazard rates corresponding to the con-
ditions described by two levels of an explanatory variable.
Two recent meta-analysis for long-term survival focused
on relative risks showed a similar result for overall survival
and disease-free survival (RR= 1.06, 95 % CI 0.96–1.18,
I2 =14%; RR=1.04, 95%CI 0.95–1.14, I2 =0%) in 4 studies
with 847 patients [23]. Though there are some other meta-
analysis focus on this topic [24, 25], odds ratios and continu-
ous variables were presented in the form of weighted mean
differences with 95% credible intervals. In systematic reviews
and meta-analysis, time-to-event outcomes are most appropri-
ately analyzed using hazard ratios. That is why we use hazard
ratio instead of odds ratio to analyze the data.
Based on the large number of patients, we also preformed a
subgroup analysis by stage to investigate whether patients
could have better disease-free survival after laparoscopic sur-
gery. Interestingly, in Bonjer’s study [12], disease-free surviv-
al for laparoscopic surgery in stage III subgroup is better than
that for open surgery. But this result is not supported when
looking at aggregate stage data. With the activating of
COLOR II trial and ACOSOG Z6051 trial, more results will
be published to make it possible to analyze overall survival
and disease-free survival at 5 years.
Another point which needs attention is the high conversion
rate. Laparoscopic surgery for rectal cancer is otherwise a
rather complicated surgery than other laparoscopic colectomy
Fig. 5 Disease-free survival rate in stages I, II, and III, reported in three trials
Fig. 4 Disease-free survival rate reported in seven trials
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because the surgical fields for rectal surgery are confined by
the narrow and deep pelvis, and total mesorectal excision and
autonomic nerve preservation are prerequisites for functional
and oncological safety [26–28].
Some limitations of this meta-analysis should also be ac-
knowledged when interpreting the results: First, neoadjuvant
chemotherapy and chemotherapy after surgery are quite impor-
tant factors which may play a role on the results [29], since
different chemotherapy strategies for laparoscopic and open sur-
gery would have unpredictable influence on the long-time out-
comes. Second, we failed to detect the relationship between
different locations of tumor and the 3-year survival due to lack
of information. The specific location may affect the surgery
approach which may bring about clinical heterogeneity between
trials. The surgical skill varied from different surgeons, which
may also have some potential effects on the outcomes.
In a word, it is clear that laparoscopic surgery has better
short-time outcomes compared with open surgery through pre-
vious research [5–7, 23]. While in this analysis which is based
on the 3-year follow-up outcomes, we concluded that there
was no significant difference between the two techniques in
terms of 3-year survival, and they are both safe and effective.
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